Left Rule, D-Dimer Measurement and Complete Ultrasonography to Rule Out Deep Vein Thrombosis During Pregnancy.
Launched by MARC RIGHINI · Oct 15, 2012
Trial Information
Current as of August 02, 2025
Unknown status
Keywords
ClinConnect Summary
In pregnant women with suspected DVT, a sure diagnosis is mandatory. Indeed, false positive tests lead to inappropriate anticoagulant treatment, which increases the risk of bleeding. Conversely, false negative tests might lead to a life-threatening thromboembolic event. Thus, accuracy of diagnostic methods used in pregnant women is crucial \[1\].
In non-pregnant patients, sequential diagnostic strategies based on 1) the assessment of clinical probability, 2) D-dimer measurement and 3) compression ultrasonography (CUS) have been widely validated \[2, 3\].
Clinical probability assessment by...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pregnant women with clinically suspected DVT
- Exclusion Criteria:
- • Age less than 18
- • No available informed consent
- • Associated suspicion of pulmonary embolism
- • Ongoing anticoagulant treatment
- • Planned anticoagulant treatment at therapeutic dosage during pregnancy
About Marc Righini
Marc Righini is a distinguished clinical trial sponsor renowned for its commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapies and cutting-edge methodologies, the organization collaborates closely with healthcare professionals and regulatory bodies to design and execute rigorous clinical trials. Marc Righini prioritizes ethical standards, patient safety, and scientific integrity, ensuring that each study contributes valuable insights to the medical community. Through strategic partnerships and a dedication to excellence, the sponsor aims to bridge the gap between research and real-world application, ultimately enhancing the quality of care across various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Geneva, , Switzerland
Patients applied
Trial Officials
Grégoire Le Gal, MD
Principal Investigator
The Ottawa Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials